(May 18, 2016, 12:25 PM EDT) -- NEW YORK — A Second Circuit U.S. Court of Appeals panel on May 17 affirmed partial summary judgment in a Lipitor False Claims Act lawsuit, agreeing that guidelines for the use of cholesterol-lowering prescription drugs cannot form the basis of claims that Pfizer Inc. marketed the drugs for off-label use (United States of America, ex rel. Dr. Jesse Polansky v. Pfizer, Inc., No. 14-4774, 2nd Cir.; 2016 U.S. App. LEXIS 8974)....